Recursion Pharmaceuticals (NASDAQ:RXRX) Share Price Crosses Below 50 Day Moving Average – Time to Sell?

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) passed below its 50-day moving average during trading on Tuesday. The stock has a 50-day moving average of $3.76 and traded as low as $3.65. Recursion Pharmaceuticals shares last traded at $3.68, with a volume of 20,684,013 shares changing hands.

Recursion Pharmaceuticals News Summary

Here are the key news stories impacting Recursion Pharmaceuticals this week:

• Positive Sentiment: New Phase 2 results for REC-4881 showed durable reductions in polyp burden in patients with familial adenomatous polyposis, including larger, higher-risk polyps and activity across the gastrointestinal tract. REC-4881 Phase 2 results
• Positive Sentiment: Third-quarter revenue climbed 258.5% to $18.55 million, above the $14.81 million consensus, helped by a $10 million Sanofi milestone payment. The loss of $0.22 per share was narrower than Zacks’ $0.24 estimate and the year-earlier $0.36 loss. Q3 results and Sanofi milestone
• Positive Sentiment: Recursion said its cash runway is expected to extend into 2029, easing near-term financing concerns. The company also appointed pharmaceutical veteran Fred Hassan as board chair. Q3 financial and business update
• Negative Sentiment: The REC-4881 registrational study is targeted for the second half of 2027, leaving a lengthy path before potential pivotal-trial progress. Recursion also remains loss-making, and valuation commentary has raised downside concerns. REC-4881 study timing and cash runway

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on RXRX shares. Morgan Stanley set a $5.90 target price on shares of Recursion Pharmaceuticals in a research report on Friday, October 16th. Needham & Company LLC reissued a “buy” rating and set a $8.00 price target on shares of Recursion Pharmaceuticals in a research report on Monday, October 19th. Wall Street Zen raised shares of Recursion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, October 17th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Thursday, October 15th. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $8.18.

Recursion Pharmaceuticals Trading Down 3.9%

The stock has a 50-day moving average of $3.76 and a two-hundred day moving average of $3.53. The company has a market cap of $1.97 billion, a P/E ratio of -4.09 and a beta of 1.15. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.03 and a current ratio of 5.03.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its earnings results on Monday, November 2nd. The company reported ($0.22) EPS for the quarter, hitting the consensus estimate of ($0.22). Recursion Pharmaceuticals had a negative return on equity of 46.47% and a negative net margin of 697.15%. The business had revenue of $18.55 million for the quarter, compared to the consensus estimate of $14.81 million. During the same period in the previous year, the company posted ($0.36) earnings per share. On average, equities research analysts predict that Recursion Pharmaceuticals, Inc. will post -0.93 earnings per share for the current year.

Insider Activity

In other news, Director Blake Borgeson sold 50,000 shares of Recursion Pharmaceuticals stock in a transaction dated Tuesday, October 6th. The stock was sold at an average price of $4.84, for a total value of $242,000.00. Following the completion of the transaction, the director owned 6,108,287 shares of the company’s stock, valued at $29,564,109.08. The trade was a 0.81% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Robert Hershberg sold 25,000 shares of Recursion Pharmaceuticals stock in a transaction dated Tuesday, October 6th. The stock was sold at an average price of $5.00, for a total value of $125,000.00. Following the completion of the transaction, the director directly owned 162,156 shares of the company’s stock, valued at approximately $810,780. This represents a 13.36% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 127,408 shares of company stock worth $546,076 over the last three months. 6.65% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. MCF Advisors LLC purchased a new stake in shares of Recursion Pharmaceuticals during the second quarter valued at approximately $27,000. Fund Advisors of America Inc FL purchased a new position in Recursion Pharmaceuticals in the 2nd quarter worth approximately $45,000. Sequoia Financial Advisors LLC raised its holdings in Recursion Pharmaceuticals by 51.5% in the 1st quarter. Sequoia Financial Advisors LLC now owns 15,162 shares of the company’s stock worth $47,000 after acquiring an additional 5,156 shares during the last quarter. QRG Capital Management Inc. purchased a new position in Recursion Pharmaceuticals in the 1st quarter worth approximately $47,000. Finally, Park Avenue Securities LLC bought a new position in Recursion Pharmaceuticals in the 3rd quarter valued at approximately $47,000. 89.06% of the stock is owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc is a biotechnology company that uses advanced computing, artificial intelligence and automated biology to discover and develop new medicines. The company’s platform, known as the Recursion Operating System, combines large-scale biological experimentation with machine learning and data analysis to identify potential drug candidates and characterize how diseases respond to treatments.

Recursion applies its technology to a range of therapeutic areas, including oncology, rare diseases, neuroscience and infectious diseases.